title: [Clinical features and factors related to the functional prognosis in Meige's syndrome].
abstract: To clarify the factors determining the amelioration of Meige's syndrome, changes of involuntary movements (IVMs) and functional disability, we examined 60 patients with Meige's syndrome during 5 years after the onset. On average, they showed gradual worsening of IVMs for approximately 2.1 years, then the IVMs ameliorated slowly. In many patients, blepharospasm appeared as the first symptom. Subsequent IVMs were seen in vicinity of the muscles of orbicularis oculi. Phasic involuntary contractions changed to tonic ones in some patients. Asynchrony of the IVMs in various facial or neck muscles may be originated from extensive pathological changes and high excitability in the brainstem. The factors determining the amelioration of functional disability are: (1) younger onset, (2) shorter duration from the onset to the period showing the worst symptoms, (3) mild IVMs when the symptoms were the worst, (4) shorter duration from the onset to the beginning of therapy, (5) synchrony of the IVMs between the muscles of orbicularis oculi and other muscles. Methylphenidate, trihexyphenidyl, and ceruletide showed a higher efficiency for IVMs than the other drugs. The drug therapy in Meige's syndrome should be started as early as possible.
authors.affiliation: Department of Neurology, School of Medicine, Chiba University.
authors.forename: I
authors.initials: I
authors.lastname: Kamitsukasa
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: Y
authors.initials: Y
authors.lastname: Tokumaru
authors.forename: K
authors.initials: K
authors.lastname: Hirayama
mesh_terms: D017668:Age of Onset; D001767:Blinking; D002108:Ceruletide / Q000627:therapeutic use; D004576:Electromyography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008538:Meige Syndrome / Q000188:drug therapy / Q000503:physiopathology*; D008774:Methylphenidate / Q000627:therapeutic use; D011379:Prognosis; D013035:Spasm; D014282:Trihexyphenidyl / Q000627:therapeutic use
chemical_list: D008774:Methylphenidate; D014282:Trihexyphenidyl; D002108:Ceruletide